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randomized to CZP at Wk0, 91% completed Wk24, 87% Wk48, and 80% Wk96. Rapid 
improvements observed to Wk24 were maintained to Wk96 for pain (Wk24 and 
Wk96; CFB: -28.5 and -31.3; MCID: 69.2% and 66.3%), fatigue (Wk24 and Wk96; CFB: 
-2.0 and -2.4; MCID: 64.1% and 60.4%), HAQ-DI (Wk24 and Wk96; CFB: -0.48 and 
-0.52; MCID: 48.7% and 48.0%), SF-36 PCS (Wk24 and Wk96; CFB: 8.01 and 9.01; MCID: 
67.4% and 60.1%), SF-36 MCS (Wk24 and Wk96; CFB: 4.50 and 3.92; MCID: 50.9% and 
43.6%), PsAQoL (Wk24 and Wk96; CFB: -3.87 and -4.50), and DLQI (Wk24 and Wk96; 
CFB: -5.8 and -6.0; MCID: 40.7% and 41.0%). Similar improvements were observed 
with both dosing regimens and in patients with or without prior anti-TNF exposure. 
Correlations were observed between improvements in PROs and DAS28 (data not 
shown). ConClusions: Improvements observed to Wk24 in generic and disease-
specific PROs were sustained to Wk96 of the RAPID-PsA trial for both CZP dosing 
regimens.
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objeCtives: Pain medication diaries have traditionally been collected via paper 
due to challenges of patients entering unlimited medications, units, dosages, and 
administration schedules. This study developed an electronic diary that permits site 
staff to enter medications that patients are taking, enables the patient to update 
medication taken and to enter new medications within the reporting period, and 
reduces the possibility of cheating behaviors during the study. Usability of this 
electronic diary was evaluated to ensure that patients in a clinical trial setting could 
successfully update their diaries in real-time to accurately track pain medication 
intake. Methods: A cross-sectional qualitative study was conducted involving 
usability interviews with patients diagnosed with osteoarthritis of the hip or knee 
who were taking pain medication. Interviews were conducted in two waves of 10 
participants each, allowing for evaluation of findings and revisions to the eDiary 
between waves. Results: Mean age of the sample (N= 20) was 66 years (range 
43-78), 90% over 60 years old; 60% were female; 95% were white; 70% completed 
secondary school or some college. In wave 1, issues were noted with training, select-
ing responses, exiting to send data, and some wording. For wave 2, the training 
module was revised to more closely match the diary, wording was revised, and a 
screen added to facilitate exiting the diary. No issues were noted with training, 4 
had trouble selecting responses, and 3 suggested additional instructions on the 
new screen. No additional changes were made following wave 2. ConClusions: 
The study showed it is possible to develop an electronic pain medication diary 
that allows patients to update their medications during a study. Extensive training 
was critical to the usability of the electronic version. The two wave study design 
provided the opportunity to detect and make changes to the eDiary with marked 
improvement in wave 2.
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objeCtives: Spondyloarthritis (SpA) is a group of diseases that share common clini-
cal, radiographic and genetic features. Axial SpA is one major subgroup including 
patients with radiographic (rad-axSpA) and non-radiographic axSpA (nr-axSpA). 
There has been limited research on axSpA patients in clinical practice and the 
impact of the disease on patient’s health-related quality of life (HrQoL). The aim 
of this study was to characterize patients with axSpA in clinical practice and to 
investigate similarities/differences between rad-axSpA and nr-axSpA with respect 
to their HrQoL. Methods: This is a longitudinal, multi-center cohort study where 
patients were consecutively recruited from Swedish clinical practice and followed 
for 3 months. At baseline, the rheumatologists registered information on disease 
history, extra articular manifestations and treatments. The patients answered 
online questionnaires capturing patient demographics, disease activity, function 
and HrQoL. HrQoL was measured using the EQ-5D and the Ankylosing Spondylitis 
Quality of Life Questionnaire (ASQoL). While higher scores in the EQ-5D indicate bet-
ter HrQoL, the opposite is true for the ASQoL. Results: 251 patients were included 
of whom 197 (78%) were classified as axial SpA. Of those, 125 (63%) were classi-
fied as rad-axSpA and 72 (37%) as nr-axSpA according to the ASAS axSpA criteria. 
There were more women in the nr-axSpA group (50%) compared with the rad-axSpA 
group (38%). The nr-axSpA patients had a shorter time between symptom onset and 
diagnosis than the rad-axSpA patients (6.7 vs. 9.0 years) and a significantly higher 
disease activity (BASDAI= 4.1 vs 2.7, p< 0.001). Mean EQ-5D score at baseline was 
0.66 for rad-axSpA and 0.61 for nr-axSpA, lower than the Swedish general popula-
tion (0.84). ASQoL scores was significantly higher in the nr-axSpA group (8.8 vs 6.4, 
p= 0.016). ConClusions: HRQoL is poorer in axial SpA patients compared to the 
general population and patients with nr-axSpA reported a higher impact on HRQoL 
than patients with rad-axSpA.
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objeCtives: Rheumatic diseases (RD) have been associated with functional and 
work-related disability due to the deliberating and progressive nature of these 
diseases and have many deleterious consequences on patients’ life. The aim of the 
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objeCtives: Despite widespread treatments for Osteoarthritis (OA), data on 
treatment patterns, adequacy of pain relief, and quality of life are limited. The 
prospective multinational Survey of Osteoarthritis Real World Therapies (SORT) 
was designed to investigate these aspects. This analysis aims to describe the clini-
cal characteristics and the patient reported outcomes of the Portuguese dataset 
of SORT baseline. Methods: The statistical analysis included, from January to 
December of 2011, 192 participants ≥ 50 years or older with primary knee OA 
from 7 health care centers in Portugal who were receiving oral or topic analgesics. 
Inadequate Pain Relief (IPR) was defined as a score > 4/10 in item 5 of the Brief Pain 
Inventory (BPI), indicating moderate to severe pain. Results: Overall, the median 
age was 67.0 ± 8.7 years and 77.6% were female. Mean duration of knee OA was 
6.3 ± 6.3 years. IPR was reported by 52.0% of the patients. The most prescribed 
analgesics were NSAIDs (88.1%), alternative therapies, including glucosamine, 
chondroitin and hyaluronate (44.3%) and paracetamol (28.6%). Patients with IPR 
scored higher than non-IPR patients in WOMAC – Stiffness (61.0 vs 39.7, p< 0.001) 
and WOMAC – physical function (59.2 vs 39.4, p< 0.001), meaning worse condi-
tion. Patients with IPR had worse quality of life related to knee osteoarthritis as 
measured by the SF-12 questionnaire (fair/poor: 86.9% vs. 72.0%, p< 0.001). 62.0% 
of patients with IPR were dissatisfied or very dissatisfied with the effects of anal-
gesics versus 34.0% of patients with non-IPR (p< 0.05). ConClusions: Despite the 
use of analgesics, over half of the Portuguese patients in SORT reported moderate 
to severe knee pain. Worse outcomes were also observed in this group regarding 
other symptoms of knee OA and general quality of life. These findings suggest 
that if an improvement of pain management in knee OA can be achieved, it may 
have high impact on patients’ lives.
PMS75
QUalitative eQUivalence betWeen a PaPer and electronic tablet 
verSion of the WoMac®nrS3.1 and Patient global aSSeSSMent
Eremenco S.1, Fleming S.2, Riordan D.3, Stringer S.1, Gleeson S.1, Sanga P.4, Kelly K.5
1Evidera, Inc., Bethesda, MD, USA, 2Janssen Global Services, Titusville, NJ, USA, 3Janssen Research 
and Development, Raritan, NJ, USA, 4Janssen Research and Development, Titusville, NJ, USA, 
5Janssen Research and Development L.L.C., Titusville, NJ, USA
objeCtives: Prior equivalence work with the WOMAC® scale was published for 
the VAS scale and older touchscreen computer technology. Additional equivalence 
evaluation of the WOMAC®NRS3.1 and the Patient Global Assessment (PGA) in a 
newer tablet with stylus was needed to document suitability of this mode of data 
collection for these instruments in upcoming clinical trials. Methods: A cross-sec-
tional qualitative study was conducted involving cognitive and usability interviews 
with patients diagnosed with osteoarthritis of the hip or knee who were taking 
pain medication for their condition. Interviews were conducted in two waves of 10 
participants each, with revisions to the PGA made in between the rounds, which 
allowed for changes to the electronic version to be evaluated. Results: Mean age 
of the sample (N= 20) was 66 years, (range 43-78), 90% over 60 years old; 60% were 
female; 95% were white; 75% were retired; 70% had completed secondary school or 
some college, while 30% had completed college or a post-graduate degree. In wave 
1, minor issues were found with completing the WOMAC®, mainly with using the 
stylus to select responses and glare on the screen. There were no issues identified 
in interpreting the response scale. For the PGA, 50% (5/10) used the wrong recall 
period (48 hours or longer). The PGA recall period was revised from “at this time” 
to “over the past 24 hours” and bolded for emphasis. In wave 2, similar issues with 
glare and stylus response were found, while 80% used the correct recall period on 
the PGA, with 20% using 48 hours. ConClusions: The study showed excellent 
qualitative equivalence between the paper and electronic WOMAC® with only minor 
usability issues. The two wave study design provided the opportunity to detect and 
make changes to the PGA recall period and formatting that showed improvement 
in the second wave.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 96 
weeks (wks) of the RAPID-PsA trial. Methods: The RAPID-PsA trial (NCT01087788) 
is double-blind and placebo-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally ran-
domized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wk0, 
Wk2, Wk4) continued on their assigned dose in the dose-blind phase and OLE. Here 
we present PRO data for the CZP-treated randomized set, including mean change 
from baseline (CFB) and Minimal Clinically Important Differences (MCIDs). Data 
were also analysed for CZP-randomized patients with (19.8%) or without (80.2%) 
prior anti-TNF exposure. Missing data were imputed by LOCF. Correlations between 
clinical outcomes and PROs were also investigated. Results: Of 273 patients 
